New POZN Investor PresentationSome nuggets in there, in addition to summing up the whole topography:
-Looks like they'll be going about selling Yosprala themselves. 110 pharma reps at launch with an estiated 300, targetting 40% of the market opportunity.
-Bezalip SR is getting some mention again. I'd noticed over the last year that TRX had continually minimized the mention of Bezalip SR for the US market as I'd assumed they were having limited success in finding a partner to develop the drug (just my guess). The drug is once again front and centre, so perhaps POZN will be able to kickstart US approval.
https://www.pozen.com/wp-content/uploads/2011/08/FINAL-POZN-IR-Presentation-July-2015.pdf
Looking good.